Why the study?
Chronic heart failure carries high mortality, morbidity, and reduced quality of life, prompting this summary of pharmacotherapy updates from the 2021 ESC guidelines.
Answers are grounded in this paper and cite their sources.
This article summarizes the 2021 European Society of Cardiology guidelines for the pharmacological management of chronic heart failure.
ChronickĂŠ srdeÄnĂ selhĂĄnĂ je onemocnÄnĂ s vysokou ĂşmrtnostĂ, nemocnostĂ a zĂĄroveĹ vedoucĂ k vĂ˝raznĂŠmu zhorĹĄenĂ kvality Ĺživota nemocnĂ˝ch. NaĹĄĂm cĂlem v lĂŠÄbÄ pacientĹŻ s tĂmto onemocnÄnĂm je zlepĹĄit jejich klinickĂ˝ stav a zĂĄroveĹ snĂĹžit jejich mortalitu a Äetnost hospitalizacĂ pro srdeÄnĂ selhĂĄnĂ. V lĂŠÄbÄ chronickĂŠho srdeÄnĂho selhĂĄnĂ doĹĄlo v poslednĂch letech k vĂ˝znamnĂŠmu pokroku, kterĂ˝ prĂĄvÄ vede ke zlepĹĄenĂ výťe uvedenĂ˝ch faktorĹŻ. V ÄlĂĄnku pĹedklĂĄdĂĄm struÄnĂŠ shrnutĂ farmakoterapie chronickĂŠho srdeÄnĂho selhĂĄnĂ, kterĂĄ byla uveĹejnÄna v novĂ˝ch guidelines EvropskĂŠ kardiologickĂŠ spoleÄnosti z roku 2021. © 2022, ÄKS.
No takes yet. Share an insight, caveat, or question.
Jaroslav Brotánek (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: